Metabolic regulation of organelle homeostasis in lupus T cells

Clinical Immunology

Volumn 144, Issue 3, 2012, Pages 200-213

  Caza, Tiffany N ^a,b   Talaber, Gergely ^a,b   Perl, Andras ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Autophagy; Endocytic recycling; Mammalian target of rapamycin; Mitochondria; Systemic lupus erythematosus; T cell

Indexed keywords

ACETYLSALICYLIC ACID; ATACICEPT; BELIMUMAB; BORTEZOMIB; FASUDIL; GLUCOCORTICOID; GLUTATHIONE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 17; INTERLEUKIN 21; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; T LYMPHOCYTE RECEPTOR;

AUTOPHAGY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ACTIVITY; FOOD AND DRUG ADMINISTRATION; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL SYNAPSE; MEMBRANE POTENTIAL; METABOLIC REGULATION; MITOPHAGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; UPREGULATION;

ANIMALS; HOMEOSTASIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; ORGANELLES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84864144757     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.07.001     Document Type: Review

References (173)

1. Tsokos G.C. Mechanisms of disease: systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
2. Edwards C.J., Cooper C. Early environmental exposure and the development of lupus. Lupus 2006, 15:814-819.
3. Moser K.L., Kelly J.A., Lessard C.J., Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 2009, 10:373-379.
4. Zhou Y., Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun. Rev. 2008, 7:376-383.
5. Deapen D., Escalante A., Weinrib L., Horwitz D., Bachman B., Roy-Burman P., Walker A., Mack T.M. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35:311-318.
6. Ma L., Chan K., Trendell-Smith N.J., Wu A., Tian L., Lam A.C., Chan A.K., Lo C., Chik S., Ko K., To C.K.W., Kam S., Li X., Yang C., Leung S.Y., Ng M., Stott D.I., MacPherson G.G., Huang F. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur. J. Immunol. 2005, 35:3364-3375.
7. Lövgren T., Eloranta M., Båve U., Alm G.V., Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004, 50:1861-1872.
8. Kovacs B., Vassilopoulos D., Vogelgesang S.A., Tsokos G.C. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-Clin. Immunol. Immunopathol. 1996, 81:293-302.
9. Gergely P., Grossman C., Niland B., Puskas F., Neupane H., Allam F., Banki K., Phillips P.E., Perl A. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46:175-190.
10. Twig G., Elorza A., Molina A.J.A., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., Alroy J., Wu M., Py B.F., Yuan J., Deeney J.T., Corkey B.E., Shirihai O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008, 27:433-446.
11. Borniquel S., Valle I., Cadenas S., Lamas S., Monsalve M. Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J. 2006, 20:1889-1891.
12. 2+ signaling profile of lupus T cells. J. Immunol. 2004, 173:3676-3683.
13. Quintana A., Schwarz E.C., Schwindling C., Lipp P., Kaestner L., Hoth M. Sustained activity of calcium release-activated calcium channels requires translocation of mitochondria to the plasma membrane. J. Biol. Chem. 2006, 281:40302-40309.
14. Quintana A., Schwindling C., Wenning A.S., Becherer U., Rettig J., Schwarz E.C., Hoth M. T cell activation requires mitochondrial translocation to the immunological synapse. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14418-14423.
15. Crispín J.C., Kyttaris V.C., Juang Y., Tsokos G.C. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol. 2008, 29:110-115.
16. Perl A., Fernandez D.R., Telarico T., Doherty E., Francis L., Phillips P.E. T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr. Opin. Rheumatol. 2009, 21:454-464.
17. Jury E.C., Kabouridis P.S., Flores-Borja F., Mageed R.A., Isenberg D.A. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 2004, 113:1176-1187.
18. Fernandez D.R., Telarico T., Bonilla E., Li Q., Banerjee S., Middleton F.A., Phillips P.E., Crow M.K., Oess S., Muller-Esterl W., Perl A. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 2009, 182:2063-2073. (Baltimore, Md.: 1950).
19. Patino-Lopez G., Dong X., Ben-Aissa K., Bernot K.M., Itoh T., Fukuda M., Kruhlak M.J., Samelson L.E., Shaw S. Rab35 and its GAP EPI64C in T cells regulate receptor recycling and immunological synapse formation. J. Biol. Chem. 2008, 283:18323-18330.
20. Bridges D., Fisher K., Zolov S.N., Xiong T., Inoki K., Weisman L.S., Saltiel A.R. Rab5 proteins regulate activation and localization of target of rapamycin complex 1. J. Biol. Chem. 2012, 287:20913-20921.
21. Powell J.D., Pollizzi K.N., Heikamp E.B., Horton M.R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 2012, 30:39-68.
22. Crispín J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., Kyttaris V.C., Juang Y., Tsokos G.C. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008, 181:8761-8766.
23. + T cells and display an inflammatory effector phenotype. J. Immunol. 2009, 183:4675-4681.
24. Scalapino K.J., Tang Q., Bluestone J.A., Bonyhadi M.L., Daikh D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 2006, 177:1451-1459.
25. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 2006, 116:1218-1222.
26. + antigen-specific autoimmune effectors in vitro and in vivo. J. Immunol. 2008, 181:3137-3147.
27. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003, 171:6173-6177.
28. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 2006, 18:670-675.
29. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183:3160-3169.
30. Enyedy E.J., Nambiar M.P., Liossis S.-C., Dennis G., Kammer G.M., Tsokos G.C. Fcε receptor type I γ chain replaces the deficient T cell receptor ζ chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44:1114-1121.
31. Krishnan S., Farber D.L., Tsokos G.C. T cell rewiring in differentiation and disease. J. Immunol. 2003, 171:3325-3331.
32. Tsokos G.C., Nambiar M.P., Tenbrock K., Juang Y. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003, 24:259-263.
33. Deng G., Liu L., Bahjat F.R., Pine P.R., Tsokos G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010, 62:2086-2092.
34. Ueda H., Howson J.M.M., Esposito L., Heward J., Snook H., Chamberlain G., Rainbow D.B., Hunter K.M.D., Smith A.N., Di Genova G., Herr M.H., Dahlman I., Payne F., Smyth D., Lowe C., Twells R.C.J., Howlett S., Healy B., Nutland S., Rance H.E., Everett V., Smink L.J., Lam A.C., Cordell H.J., Walker N.M., Bordin C., Hulme J., Motzo C., Cucca F., Hess J.F., Metzker M.L., Rogers J., Gregory S., Allahabadia A., Nithiyananthan R., Tuomilehto-Wolf E., Tuomilehto J., Bingley P., Gillespie K.M., Undlien D.E., Rønningen K.S., Guja C., Ionescu-Tirgovişte C., Savage D.A., Maxwell A.P., Carson D.J., Patterson C.C., Franklyn J.A., Clayton D.G., Peterson L.B., Wicker L.S., Todd J.A., Gough S.C.L. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
35. Holst J., Wang H., Eder K.D., Workman C.J., Boyd K.L., Baquet Z., Singh H., Forbes K., Chruscinski A., Smeyne R., van Oers N.S.C., Utz P.J., Vignali D.A.A. Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat. Immunol. 2008, 9:658-666.
36. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
37. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985-988.
38. Takahashi S., Kataoka H., Hara S., Yokosuka T., Takase K., Yamasaki S., Kobayashi W., Saito Y., Saito T. In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur. J. Immunol. 2005, 35:399-407.
39. Nambiar M.P., Fisher C.U., Warke V.G., Krishnan S., Mitchell J.P., Delaney N., Tsokos G.C. Reconstitution of deficient T cell receptor ζ chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003, 48:1948-1955.
40. Smith-Garvin J.E., Koretzky G.A., Jordan M.S. T cell activation. Annu. Rev. Immunol. 2009, 27:591-619.
41. Crispín J.C., Keenan B.T., Finnell M.D., Bermas B.L., Schur P., Massarotti E., Karlson E.W., Fitzgerald L.M., Ergin S., Kyttaris V.C., Tsokos G.C., Costenbader K.H. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 2010, 62:1431-1437.
42. Crispín J.C., Liossis S.-C., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y., Tsokos G.C. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 2010, 16:47-57.
43. Perl A., Gergely P., Banki K. Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int. Rev. Immunol. 2004, 23:293-313.
44. Quintana A., Hoth M. Mitochondrial dynamics and their impact on T cell function. Cell Calcium 2012, 52:57-63.
45. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2983-2988.
46. Hüttemann M., Lee I., Pecinova A., Pecina P., Przyklenk K., Doan J.W. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J. Bioenerg. Biomembr. 2008, 40:445-456.
47. Palmer C.S., Osellame L.D., Stojanovski D., Ryan M.T. The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell. Signal. 2011, 23:1534-1545.
48. Wang K., Klionsky D.J. Mitochondria removal by autophagy. Autophagy 2011, 7:297-300.
49. Pua H.H., Guo J., Komatsu M., He Y. Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J. Immunol. 2009, 182:4046-4055.
50. Baranda L., de la Fuente H., Layseca-Espinosa E., Portales-Pérez D., Niño-Moreno P., Valencia-Pacheco G., Abud-Mendoza C., Alcocer-Varela J., González-Amaro R. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology 2005, 44:1507-1513.
51. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33:35-41.
52. Dolff S., Abdulahad W.H., Van Dijk M.C.R.F., Limburg P.C., Kallenberg C.G.M., Bijl M. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann. Rheum. Dis. 2010, 69:2034-2041.
53. Ivanova A.V., Ivanov S.V., Pascal V., Lumsden J.M., Ward J.M., Morris N., Tessarolo L., Anderson S.K., Lerman M.I. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J. Pathol. 2007, 211:591-601.
54. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C.L., Joyce S., Peschon J.J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191:771-780.
55. Schwindling C., Quintana A., Krause E., Hoth M. Mitochondria positioning controls local calcium influx in T cells. J. Immunol. 2010, 184:184-190.
56. Chang C., Blackstone C. Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann. N. Y. Acad. Sci. 2010, 1201:34-39.
57. Baixauli F., Martín-Cófreces N.B., Morlino G., Carrasco Y.R., Calabia-Linares C., Veiga E., Serrador J.M., Sánchez-Madrid F. The mitochondrial fission factor dynamin-related protein 1 modulates T-cell receptor signalling at the immune synapse. EMBO J. 2011, 30:1238-1250.
58. Nagy G., Koncz A., Fernandez D., Perl A. Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic. Biol. Med. 2007, 42:1625-1631.
59. Perl A., Gergely P., Nagy G., Koncz A., Banki K. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 2004, 25:360-367.
60. 2+- and redox-dependent production of nitric oxide. J. Immunol. 2003, 171:5188-5197.
61. Kis-Toth K., Tsokos G.C. Dendritic cell function in lupus: independent contributors or victims of aberrant immune regulation. Autoimmunity 2010, 43:121-130.
62. Gergely P., Niland B., Gonchoroff N., Pullmann R., Phillips P.E., Perl A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J. Immunol. 2002, 169:1092-1101.
63. Vyshkina T., Sylvester A., Sadiq S., Bonilla E., Canter J.A., Perl A., Kalman B. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin. Immunol. 2008, 129:31-35.
64. Z. Lai, R. Hanczko, E. Bonilla, T.N. Caza, B. Clair, A. Bartos, G. Miklossy, J. Jimah, E. Doherty, H. Tily, L. Francis, R. Garcia, M. Dawood, J. Yu, I. Ramos, I. Coman, S.V. Faraone, P.E. Phillips, A. Perl, N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients, Arthritis Rheum. in press, http://dx.doi.org/10.1002/art.34502.
65. Perez-Sanchez C., Ruiz-Limon P., Aguirre M.A., Bertolaccini M.L., Khamashta M.A., Rodriguez-Ariza A., Segui P., Collantes-Estevez E., Barbarroja N., Khraiwesh H., Gonzalez-Reyes J.A., Villalba J.M., Velasco F., Cuadrado M.J., Lopez-Pedrera C. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 2012, 119:5859-5870.
66. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
67. Haidinger M., Poglitsch M., Geyeregger R., Kasturi S., Zeyda M., Zlabinger G.J., Pulendran B., Hörl W.H., Säemann M.D., Weichhart T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J. Immunol. 2010, 185:3919-3931.
68. Song J., Salek-Ardakani S., So T., Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat. Immunol. 2007, 8:64-73.
69. Powell J.D., Lerner C.G., Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 1999, 162:2775-2784.
70. Rao R.D., Buckner J.C., Sarkaria J.N. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr. Cancer Drug Targets 2004, 4:621-635.
71. Zeng L.-, Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
72. Huang X., Zhang H., Yang J., Wu J., McMahon J., Lin Y., Cao Z., Gruenthal M., Huang Y. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 2010, 40:193-199.
73. Sampson J.R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem. Soc. Trans. 2009, 37:259-264.
74. Teachey D.T., Greiner R., Seif A., Attiyeh E., Bleesing J., Choi J., Manno C., Rappaport E., Schwabe D., Sheen C., Sullivan K.E., Zhuang H., Wechsler D.S., Grupp S.A. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br. J. Haematol. 2009, 145:101-106.
75. Warner L.M., Adams L.M., Sehgal S.N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994, 37:289-297.
76. Lui S.L., Yung S., Tsang R., Zhang F., Chan K.W., Tam S., Chan T.M. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice. Lupus 2008, 17:305-313.
77. Ramos-Barrón Á., Piñera-Haces C., Gõmez-Alamillo C., Santiuste-Torcida I., Ruiz J.C., Buelta-Carrillo L., Merino R., De Francisco Á.L.M., Arias M. Prevention of murine lupus disease in (NZB X NZW)F 1 mice by sirolimus treatment. Lupus 2007, 16:775-781.
78. Lui S.L., Tsang R., Chan K.W., Zhang F., Tam S., Yung S., Chan T.M. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 2008, 23:2768-2776.
79. Hou L.-, He S.-, Li X., Yang Y., He P.-, Zhou Y., Zhu F.-, Yang Y.-, Li Y., Tang W., Zuo J.- Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011, 63:2445-2455.
80. Reddy P.S., Legault H.M., Sypek J.P., Collins M.J., Goad E., Goldman S.J., Liu W., Murray S., Dorner A.J., O'Toole M. Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res. Ther. 2008, 10.
81. Yoshizaki A., Yanaba K., Yoshizaki A., Iwata Y., Komura K., Ogawa F., Takenaka M., Shimizu K., Asano Y., Hasegawa M., Fujimoto M., Sato S. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010, 62:2476-2487.
82. Schwarting A., Tesch G., Kinoshita K., Maron R., Weiner H.L., Kelley V.R. IL-12 drives IFN-γ-dependent autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 1999, 163:6884-6891.
83. Schwarting A., Wada T., Kinoshita K., Tesch G., Kelley V.R. IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 1998, 161:494-503.
84. Balomenos D., Rumold R., Theofilopoulos A.N. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 1998, 101:364-371.
85. Jie G., Jiang Q., Rui Z., Yifei Y. Expression of interleukin-17 in autoimmune dacryoadenitis in MRL/lpr mice. Curr. Eye Res. 2010, 35:865-871.
86. Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander Heiden M.G., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 39:171-183.
87. + T cell subsets. J. Immunol. 2011, 186:3299-3303.
88. Hahn-Windgassen A., Nogueira V., Chen C., Skeen J.E., Sonenberg N., Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 2005, 280:32081-32089.
89. Ramanathan A., Schreiber S.L. Direct control of mitochondrial function by mTOR. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22229-22232.
90. Schieke S.M., Phillips D., McCoy J.P., Aponte A.M., Shen R., Balaban R.S., Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281:27643-27652.
91. Cunningham J.T., Rodgers J.T., Arlow D.H., Vazquez F., Mootha V.K., Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex. Nature 2007, 450:736-740.
92. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., Worley P.F., Kozma S.C., Powell J.D. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
93. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., Xiao B., Worley P.F., Powell J.D. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-304.
94. + regulatory T cells. Blood 2005, 105:4743-4748.
95. Sarbassov D.D., Sabatini D.M. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 2005, 280:39505-39509.
96. Yoshida S., Hong S., Suzuki T., Nada S., Mannan A.M., Wang J., Okada M., Guan K., Inoki K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 2011, 286:32651-32660.
97. Suwannaroj S., Lagoo A., Keisler D., McMurray R.W. Antioxidants suppress mortality in the female NZB×NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001, 10:258-265.
98. Tewthanom K., Janwitayanujit S., Totemchockcyakarn K., Panomvana Na Ayudhya D. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J. Clin. Pharm. Ther. 2010, 35:483-485.
99. Michelot A., Costanzo M., Sarkeshik A., Boone C., Yates J.R., Drubin D.G. Reconstitution and protein composition analysis of endocytic actin patches. Curr. Biol. 2010, 20:1890-1899.
100. Flinn R.J., Yan Y., Goswami S., Parker P.J., Backer J.M. The late endosome is essential for mTORC1 signaling. Mol. Biol. Cell 2010, 21:833-841.
101. Li L., Kim E., Yuan H., Inoki K., Goraksha-Hicks P., Schiesher R.L., Neufeld T.P., Guan K. Regulation of mTORC1 by the Rab and Arf GTPases. J. Biol. Chem. 2010, 285:19705-19709.
102. Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M. Ragulator-rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
103. Ögmundsdóttir M.H., Heublein S., Kazi S., Reynolds B., Visvalingam S.M., Shaw M.K., Goberdhan D.C.I. Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes. PLoS One 2012, 7.
104. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., Sabatini D.M. The rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
105. Liu H., Rhodes M., Wiest D.L., Vignali D.A.A. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 2000, 13:665-675.
106. Krangel M.S. Endocytosis and recycling of the T3-T cell receptor complex. The role of T3 phosphorylation. J. Exp. Med. 1987, 165:1141-1159.
107. Tax W.J.M., Van der Heijden H.M.W., Capel P.J.A., Koene R.A.P. Internalization (but no recycling) of T cell receptor, T3 antigen, and other T cell antigens. Transplant. Proc. 1987, 19:273-276.
108. Nagy G., Ward J., Mosser D.D., Koncz A., Gergely P., Stancato C., Qian Y., Fernandez D., Niland B., Grossman C.E., Telarico T., Banki K., Perl A. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J. Biol. Chem. 2006, 281:34574-34591.
109. Naramura M., Jang I., Kole H., Huang F., Haines D., Gu H. C-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 2002, 3:1192-1199.
110. Cormont M., Metón I., Mari M., Monzo P., Keslair F., Gaskin C., McGraw T.E., Le Marchand-Brustel Y. CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. Traffic 2003, 4:97-112.
111. Sahu R., Kaushik S., Clement C.C., Cannizzo E.S., Scharf B., Follenzi A., Potolicchio I., Nieves E., Cuervo A.M., Santambrogio L. Microautophagy of cytosolic proteins by late endosomes. Dev. Cell 2011, 20:131-139.
112. Drake J.R., Webster P., Gambier J.C., Mellman I. Delivery of B cell receptor-internalized antigen to endosomes and class II vesicles. J Exp Med 1997, 186:1299-1306.
113. Wolf P.R., Ploegh L. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell Dev. Biol. 1995, 11:267-306.
114. Pochynyuk O., Stockand J.D., Staruschenko A. Ion channel regulation by Ras, Rho, and Rab small GTPases. Exp. Biol. Med. 2007, 232:1258-1265.
115. Lazzarino D.A., Blier P., Mellman I. The monomeric guanosine triphosphatase rab4 controls an essential step on the pathway of receptor-mediated antigen processing in B cells. J Exp Med 1998, 188:1769-1774.
116. Lleo A., Invernizzi P., Selmi C., Coppel R.L., Alpini G., Podda M., Mackay I.R., Gershwin M.E. Autophagy: highlighting a novel player in the autoimmunity scenario. J. Autoimmun. 2007, 29:61-68.
117. Crotzer V.L., Blum J.S. Autophagy and its role in MHC-mediated antigen presentation. J. Immunol. 2009, 182:3335-3341.
118. Chua C.E.L., Gan B.Q., Tang B.L. Involvement of members of the Rab family and related small GTPases in autophagosome formation and maturation. Cell Mol. Life Sci. 2011, 68:3349-3358.
119. Pei G., Bronietzki M., Gutierrez M.G. Immune regulation of Rab proteins expression and intracellular transport. J. Leukoc. Biol. 2012, 92:41-50.
120. Harigai M., Kawamoto M., Hara M., Kubota T., Kamatani N., Miyasaka N. Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J. Immunol. 2008, 181:2211-2219.
121. Davas E.M., Tsirogianni A., Kappou I., Karamitsos D., Economidou I., Dantis P.C. Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin. Rheumatol. 1999, 18:17-22.
122. Alvarcz-Dominguez C., Stahl P.D. Interferon-γ/selectively induces Rab5a synthesis and processing in mononuclear cells. J. Biol. Chem. 1998, 273:33901-33904.
123. Wainszelbaum M.J., Proctor B.M., Pontow S.E., Stahl P.D., Barbieri M.A. IL4/PGE2 induction of an enlarged early endosomal compartment in mouse macrophages is Rab5-dependent. Exp Cell Res 2006, 312:2238-2251.
124. Bhattacharya M., Ojha N., Solanki S., Mukhopadhyay C.K., Madan R., Patel N., Krishnamurthy G., Kumar S., Basu S.K., Mukhopadhyay A. IL-6 and IL-12 specifically regulate the expression of Rab5 and Rab7 via distinct signaling pathways. EMBO J. 2006, 25:2878-2888.
125. Florey O., Overholtzer M. Autophagy proteins in macroendocytic engulfment. Trends Cell Biol. 2012, 22:374-380.
126. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
127. Kuballa P., Nolte W.M., Castoreno A.B., Xavier R.J. Autophagy and the immune system. Annu. Rev. Immunol. 2012, 30:611-646.
128. Arsov I., Adebayo A., Kucerova-Levisohn M., Haye J., MacNeil M., Papavasiliou F.N., Yue Z., Ortiz B.D. A role for autophagic protein Beclin 1 early in lymphocyte development. J. Immunol. 2011, 186:2201-2209.
129. Pua H.H., Dzhagalov I., Chuck M., Mizushima N., He Y. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med 2007, 204:25-31.
130. Hubbard V.M., Valdor R., Patel B., Singh R., Cuervo A.M., Macian F. Macroautophagy regulates energy metabolism during effector T cell activation. J. Immunol. 2010, 185:7349-7357.
131. Kovacs J.R., Li C., Yang Q., Li G., Garcia I.G., Ju S., Roodman D.G., Windle J.J., Zhang X., Lu B. Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death Differ 2012, 19:144-152.
132. Jia W., He Y. Temporal regulation of intracellular organelle homeostasis in T lymphocytes by autophagy. J. Immunol. 2011, 186:5313-5322.
133. Jia W., Pua H.H., Li Q., He Y. Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes. J. Immunol. 2011, 186:1564-1574.
134. Lioudyno M.I., Kozak J.A., Penna A., Safrina O., Zhang S.L., Sen D., Roos J., Stauderman K.A., Cahalan M.D. Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2011-2016.
135. Gomes L.C., Benedetto G.D., Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol 2011, 13:589-598.
136. Willinger T., Flavell R.A. Canonical autophagy dependent on the class III phosphoinositide-3 kinase Vps34 is required for naive T-cell homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8670-8675.
137. Vassilopoulos D., Kovacs B., Tsokos G.C. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J. Immunol. 1995, 155:2269-2281.
138. Jacob N., Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13.
139. Telarico T., Doherty E., Clair B., Malorni W., Perl A. Overexpression of lupus-susceptibility gene HRES-1/Rab4 causes enhanced microautophagy and defective mitochondrial macroautophagy (mitophagy) in lupus T cells. Arthritis Rheum. 2011, 63(10):S649. (supplement).
140. Gros F., Arnold J., Page N., Decossas M., Korganow A., Martin T., Muller S. Macroautophagy is deregulated in murine and human lupus T lymphocytes. Autophagy 2012, 8(7).
141. Towns R., Kabeya Y., Yoshimori T., Guo C., Shangguan Y., Hong S., Kaplan M., Klionsky D.J., Wiley J.W. Sera from patients with type 2 diabetes and neuropathy induce autophagy and colocalization with mitochondria in SY5Y cells. Autophagy 2005, 1:163-170.
142. Zhou X., Lu X., LV J., Yang H., Qin L., Zhao M., Su Y., Li Z., Zhang H. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann. Rheum. Dis. 2011, 70:1330-1337.
143. Alirezaei M., Fox H.S., Flynn C.T., Moore C.S., Hebb A.L.O., Frausto R.F., Bhan V., Kiosses W.B., Whitton J.L., Robertson G.S., Crocker S.J. Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy 2009, 5:152-158.
144. Kužnik A., Benčina M., Švajger U., Jeras M., Rozman B., Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 2011, 186:4794-4804.
145. Page N., Schall N., Strub J.-, Quinternet M., Chaloin O., Décossas M., Cung M.T., Van Dorsselaer A., Briand J.-, Muller S. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells. PLoS One 2009, 4.
146. Page N., Gros F., Schall N., Décossas M., Bagnard D., Briand J., Muller S. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann. Rheum. Dis. 2011, 70:837-843.
147. Muller S., Monneaux F., Schal N., Rashkov R.K., Oparanov B.A., Wiesel P., Geiger J., Zimmer R. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008, 58:3873-3883.
148. Harr M.W., McColl K.S., Zhong F., Molitoris J.K., Distelhorst C.W. Glucocorticoids downregulate Fyn and inhibit IP3-mediated calcium signaling to promote autophagy in T lymphocytes. Autophagy 2010, 6:912-921.
149. Wu W.K.K., Sakamoto K.M., Milani M., Aldana-Masankgay G., Fan D., Wu K., Lee C.W., Cho C.H., Yu J., Sung J.J.Y. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resist. Updat. 2010, 13:87-92.
150. Francis L., Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert. Opin. Pharmacother. 2009, 10:1481-1494.
151. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 2010, 69:20-28.
152. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., Stohl W., Ginzler E.M., Hough D.R., Zhong Z.J., Freimuth W., Van Vollenhoven R.F. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-3930.
153. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
154. Melander C., Sallée M., Trolliet P., Candon S., Belenfant X., Daugas E., Rémy P., Zarrouk V., Pillebout E., Jacquot C., Boffa J., Karras A., Masse V., Lesavre P., Elie C., Brocheriou I., Knebelmann B., Noël L., Fakhouri F. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 2009, 4:579-587.
155. Dörner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 2006, 8.
156. Daridon C., Blassfeld D., Reiter K., Mei H.E., Giesecke C., Goldenberg D.M., Hansen A., Hostmann A., Frölich D., Dörner T. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12.
157. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T.H., Kalden J.R., Manz R.A., Voll R.E. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008, 14:748-755.
158. Wang Y., Hu Q., Madri J.A., Rollins S.A., Chodera A., Matis L.A. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8563-8568.
159. Bao L., Haas M., Kraus D.M., Hack B.K., Rakstang J.K., Holers V.M., Quigg R.J. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J. Am. Soc. Nephrol. 2003, 14:670-679.
160. Barrat F., Meeker T., Chan J., Guiducci C., Coffman R. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37:3582-3586.
161. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., Kalunian K., Dhar P., Vincent E., Pena-Rossi C., Wofsy D., Alum N., Dubois A., Kinnman N., Picard M., Bortolotti A., O'Grady L., Hill J., Nestorov I., Salmon E. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007, 56:4142-4150.
162. Sthoeger Z.M., Sharabi A., Molad Y., Asher I., Zinger H., Dayan M., Mozes E. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J. Autoimmun. 2009, 33:77-82.
163. Cardiel M.H., Tumlin J.A., Furie R.A., Wallace D.J., Joh T., Linnik M.D., Abeles M., Aelion J., Appel G.B., Aranow C., Ballou S., Becker M.A., Belmont H.M., Boling E.P., Bombardieri S., Brodeur J., Buyon J., Condemi J.J., Cronin M.E., Cush J.J., DeHoratius R., Desir D., Donohue J., Edwards M., El-Shahawy M.A., Emery P., Ensworth S., Espinoza L.R., Fondal M., Fortin P., Geppert T., Gilkeson G.S., Ginzler E., Gorevic P., Granda J., Grossman J., Hiepe F., Howard P., Hura C.E., Jaffer A., Jakes J., Kalden J.R., Kammer G.M., Kaplan M.J., Kaplan S., Katz R., Kennedy A., Kenney H.M., Khamashta M., Kivitz A.J., Kovacs C., Krishnan M., Kurtzman N.A., Liebling M., Lourie S.H., Loveless J., Manion C.V., Manzi S., Martin K., McKay J., Mease P.J., Merrill J.T., Moreland L.W., Moritz C., Neuwelt C.M., Petri M., Pogue B.C., Quinet R.J., Ramsey-Goldman R., Roth A., Rothfield N., Scarpa N., Schneider M., Shergy W.J., Sherrer Y., Sibilia J., Sisay M., Smith D., Spinowitz B., Spira M., Stevens M.P., Sturfelt G., Surbeck W., Tindall E.A., Torres A., Van Vollenhoven R., Vijayan A., Vilardell-Tarres M., Weaver C., Williams G.W., Zummer M. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008, 58:2470-2480.
164. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., Bae S.C., Sigal L., Becker J.-, Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62:3077-3087.
165. Hu Y.-, Metz D.P., Chung J., Siu G., Zhang M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 2009, 182:1421-1428.
166. Ichinose K., Juang Y., Crispín J.C., Kis-Toth K., Tsokos G.C. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2011, 63:523-529.
167. Barber D.F., Bartolomé A., Hernandez C., Flores J.M., Redondo C., Fernandez-Arias C., Camps M., Rückle T., Schwarz M.K., Rodríguez S., Martinez-A C., Balomenos D., Rommel C., Carrera A.C. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 2005, 11:933-935.
168. Kyttaris V.C., Zhang Z., Kampagianni O., Tsokos G.C. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011, 63:2058-2066.
169. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., Fleisher T., Balow J.E., Lipsky P.E. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62:542-552.
170. Stirzaker R.A., Biswas P.S., Gupta S., Song L., Bhagat G., Pernis A.B. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012, 21:656-661.
171. Llorente L., Richaud-Patin Y., García-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., Alcocer-Varela J., Grangeot-Keros L., Alarcón-Segovia D., Wijdenes J., Galanaud P., Emilie D. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43:1790-1800.
172. Ostendorf B., Iking-Konert C., Kurz K., Jung G., Sander O., Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 2005, 64:630-633.
173. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., Zhang J., White B., Coyle A.J., Kiener P.A., Jallal B. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1785-1796.